Cargando…
Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections
This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection.
Autores principales: | Park, Minah, Tan, Kelvin Bryan, Vasoo, Shawn, Dickens, Borame L., Lye, David, Cook, Alex R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984772/ https://www.ncbi.nlm.nih.gov/pubmed/35380647 http://dx.doi.org/10.1001/jamanetworkopen.2022.5750 |
Ejemplares similares
-
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study
por: Koo, Joel R, et al.
Publicado: (2020) -
The impact of earlier reopening to travel in the Western Pacific on SARS-CoV-2 transmission
por: Jin, Shihui, et al.
Publicado: (2022) -
Estimating transmission dynamics of SARS-CoV-2 at different intraspatial levels in an institutional outbreak
por: Jin, Shihui, et al.
Publicado: (2022) -
Modelling the Impact of Mass Testing to Transition from Pandemic Mitigation to Endemic COVID-19
por: Koo, Joel R, et al.
Publicado: (2022) -
Revealing regional disparities in the transmission potential of SARS-CoV-2 from interventions in Southeast Asia
por: Lim, Jue Tao, et al.
Publicado: (2020)